Overview
RPRX market data
Price History
RPRX price chart · 1M
- O
- 61.72
- H
- 62.11
- L
- 61.55
- C
- 61.80
- Vol
- 81,741.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $61.72
- Previous Close
- $62.08
- Day High
- $62.11
- Day Low
- $61.55
- 52 Week High
- $62.45
- 52 Week Low
- $44.53
- 7 Day Return
- +0.11%
- 30 Day Return
- +5.70%
- 90 Day Return
- +13.92%
- 1 Year Return
- +36.70%
- Daily Notional Volume
- $5.1M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 41.11 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.37 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.42 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 3.0% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 32.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $34.08 – $62.46 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $33.5B · P/B 3.44 · P/S 13.21.
Company News
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder DrugBenzinga · Aug 13, 2026, 5:07 PM
Royalty Pharma Announces $100M Agreement To Acquire Zealand Pharma's Rusfertide Economics, Including 1% Global Royalty; $50M At Closing, $50M On First AnniversaryBenzinga · Aug 12, 2026, 8:23 PM
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62Benzinga · Aug 7, 2026, 4:46 PM
8-K filing — Royalty Pharma plc (RPRX)SEC EDGAR · Aug 5, 2026, 11:33 AM
Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M EstimateBenzinga · Aug 5, 2026, 11:27 AM
AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market SessionBenzinga · Aug 3, 2026, 12:01 PM
Neurimmune Sells Portion Of Its Royalty Interest In Cliramitug To Royalty Pharma For Up To $425M, Including $125M UpfrontBenzinga · Jul 22, 2026, 10:54 AM
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65Benzinga · Jul 13, 2026, 6:06 PM
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next TrialBenzinga · Jul 7, 2026, 6:25 PM
Zymeworks Targets Long-Term Cash Generation Through Theravance AcquisitionBenzinga · Jun 29, 2026, 1:25 PM